作者投稿
专家审稿
编辑办公
邮件订阅
RSS
-
摘要: 克罗恩病(Crohn's disease，CD)是一种发病机制复杂的慢性炎症性肠病。近年来，靶向治疗的广泛应用显著改善了CD患者的预后。若能在靶向治疗早期进行疗效评估，将有利于筛选出治疗获益的患者，同时可对治疗无效的患者及时调整治疗方案。超声在CD活动性评估、疗效评价方面具有准确性高、无电离辐射、患者接纳程度高的优势，在CD早期疗效评估方面具有潜在临床应用价值。本文就超声在CD靶向治疗早期疗效评估中的应用进行综述，以期为优化CD患者的治疗方案提供借鉴。Abstract: Crohn's disease (CD) is a chronic inflammatory bowel disease with complicated pathogenesis and prolonged condition. In recent years, with the development of targeted therapy, biological agents have been widely used in the treatment of CD, which has significantly improved the prognosis of CD patients. If the efficacy evaluation can be carried out at the early stage of targeted therapy, it may help to figure out the patients who can benefit from the treatment and optimize the treatment plan for the ineffective patients in time. In the evaluation of CD activity and efficacy, ultrasound has the advantages of high accuracy, no radiation and high patient acceptance, and therefore has potential clinical application value in the early efficacy evaluation of CD targeted therapy. This article reviews the research progress to provides a reference for optimizing the treatment plan for CD patients.
-
Keywords:
- ultrasonography /
- early efficacy /
- Crohn's disease /
- targeted therapy
-
人们对缓和医疗的概念可能并不生疏，但对其认识尚且不够，对其理解抑或存在较大偏颇。无论是医生还是公众，都需要加深对缓和医疗重要性的认识，同时更深入地践行这一理念。
1. 人文理念是缓和医疗的本源
所谓缓和医疗，是指对慢性疾病、不可自愈/难以治愈之症、疾病晚期患者或年迈体弱者，医疗不力或救治无方，为尊重病患及其家人的意愿，为减轻其痛苦和症状，改善生命或生活质量的一种医疗对策[1]。
事实上，疾病晚期患者临近死亡(或称濒死)，是正常的生命过程。缓和医疗也是医疗过程，包含心理调适、营养支持、症状缓解、康复保健、改善预后、慰藉家人等，与延长生命并不矛盾。这些对策和措施，正是人文理念和人文关怀的体现，亦是医学及缓和医疗的本源[2]。正如特鲁多的墓志铭所阐述的，“有时是治愈，常常是帮助，而总是慰籍”。
“和缓是悉”，由来久矣。早在我国南朝，谢灵运的《山居赋》中即写道: “雷桐是别，和缓是悉”。雷、桐是古代的两位药学先祖，和、缓是古代两位名医，药神辨识草药之别，医圣明确病患之悉。尽管如此，面对诸多疾病，往往神药亦无力，圣医亦无方。此时，或者“古方治今病，和缓技亦穷”，或者人们还在留恋是否“如彼久病者，不敢忘和缓”还是“疏淪(音同药)费虽多，尺寸皆有功”呢？
于是，我们必须承认，此时最好的医疗是人文关怀，即“和缓是悉”。这就是医圣和、缓留给我们的无价财富与医疗真谛！
2. 缓和医疗是终极关怀的实施
缓和医疗涉及两个重要概念: 临终关怀(terminal care or hospice care)和终极关怀(ultimate concern)[3]。二者是不同的，临终关怀更侧重于具体的医疗措施，“临终”二字又显得狭隘、刺耳和难耐。而终极关怀则是对于生命的终极认识，比如生老病死、苦难痛殇。终极关怀其实是个哲学问题，亦是我们现今惯常的所谓“三观”(世界观、人生观、价值观)，这里侧重于对生命、身体、生活、健康、疾病与死亡的认识、理解和态度。这是每个人都必须面对，且必然要经历和选择的。
诞生或者死亡，发育或者缺陷，健康或者罹病，是科学的、生物学的、哲学的，也是自然的、宗教的、神秘的。医学当然要遵循自然规律和生命规律，但也有可能打破生死的自然轨迹，从而误导人类抗拒必然的生命过程。问题是作为医者，我们需要真正理解什么是生命的意义，以及什么是死亡的意义。现实中，我们确实在寻找消除病痛、延长生命的药物和方法，但也应该避免无意义的，甚至善意的扰乱。我们应该清楚地认识到，长生不老、无疾而终、健康长寿、万寿无疆，只不过是敬语和神话。
有了对于终极关怀的认识和理解，有了对于临终关怀的具体办法，我们对于缓和医疗就有了更深层次的认识和领会，也有助于更好地开展缓和医疗工作。可以认为，终极关怀是临终关怀或缓和医疗的目标和升华，临终关怀或缓和医疗是终极关怀的体现和实施。
3. 科学的认识论与医学的发展观
医学是一个复杂的认知系统，是自然科学与社会科学或人文科学的结合。其关乎国家、民族、社会、家庭、个人健康及幸福。所谓“天地神圣，生命至上”。为此，我们要实施全生命周期的健康管理。所谓全生命周期，就是从生到死的人生各个阶段。现阶段，缓和医疗可能更多实施于年长者，但在生命的各个阶段我们都会遇到不同的健康问题，缓和医疗理念在这些阶段具有同样重要的意义。
医学的认识和实践有两个明显的特征：一是局限性，二是风险性。所谓局限性，就是认知的局限，由于人体的复杂性以及人与环境(自然与社会)的交叉性，形成了诸多影响和变数。因此，我们对于疾病的认识和处理可能是局限的、片面的，甚至是错误的。二是风险性，因为医疗的对象是活的人体，诊断、治疗、药物、手术等都会有风险，是“危险的丛林”。先哲们告诫我们，临床工作“如临深渊，如履薄冰”，要“戒慎恐惧”。
近二三十年，医学在其他各个学科，特别是在遗传学、分子生物学、机械工艺学等技术的推动下，于颠簸中快速发展。诚然，技术的进步给医疗领域带来了巨大推动力，但也带来了诸多问题。过度诊断、过度治疗，过分相信和依赖机器检查及化验报告，脱离临床、脱离实际等的倾向日趋严重。数字化冲淡了医学的人文观念, 隔离了医生与患者，这给临床医学带来了巨大影响，却也进一步凸显了缓和医疗的重要性。
4. 小结
缓和医疗方兴未艾，可以说其是个幸运者，同时又是个逆行者。未来，缓和医疗必须紧密联系临床，既要走到患者床边去做面对面的具体工作，更要进行多学科协作，共同管理患者全生命周期各个阶段的各种问题。无论是大医院还是小诊所，缓和医疗都同样重要，都要践行和发展这一理念。北京协和医院是全国疑难重症诊疗中心，是医疗、教学和科研的结合与转化基地，应该在推动缓和医疗发展中发挥引领和示范作用，因此任重而道远。
缓和医疗不是一枝奇葩的花朵，而是一片关爱的森林。
作者贡献：秦菁负责资料收集和论文撰写；朱庆莉负责论文修订并审阅定稿。利益冲突：所有作者均声明不存在利益冲突 -
表 1 超声克罗恩病活动性评分系统
Table 1 International bowel ultrasound segmental activity score
参数 正常 不确定 活动期 肠壁厚度 ≤3 mm - ＞3 mm 肠周系膜脂肪回声 0=无 1=不确定 2=有 肠壁血流 0=无 1=短条状血流 2=肠壁内长条状血流；3=肠壁内外长条状血流 肠壁分层 0=正常 1=不确定 2=局部(≤3 cm)；3=弥漫(＞3 cm) 
下载: 导出CSV
-
[1] Lichtenstein G R, Loftus E V, Isaacs K L, et al. ACG clinical guideline: management of Crohn's disease in adults[J]. Am J Gastroenterol, 2018, 113(4): 481-517. DOI: 10.1038/ajg.2018.27
[2] Ilvemark J F K F, Hansen T, Goodsall T M, et al. Defining transabdominal intestinal ultrasound treatment response and remission in inflammatory bowel disease: systematic review and expert consensus statement[J]. J Crohns Colitis, 2022, 16(4): 554-580. DOI: 10.1093/ecco-jcc/jjab173
[3] Drews B H, Barth T F E, Hänle M M, et al. Comparison of sonographically measured bowel wall vascularity, histo-logy, and disease activity in Crohn's disease[J]. Eur Radiol, 2009, 19(6): 1379-1386. DOI: 10.1007/s00330-008-1290-5
[4] Novak K L, Nylund K, Maaser C, et al. Expert consensus on optimal acquisition and development of the international bowel ultrasound segmental activity score[IBUS-SAS]: a reliability and inter-rater variability study on intestinal ultrasonography in Crohn's disease[J]. J Crohns Colitis, 2021, 15(4): 609-616. DOI: 10.1093/ecco-jcc/jjaa216
[5] Dragoni G, Gottin M, Innocenti T, et al. Correlation of ultrasound scores with endoscopic activity in Crohn's disease: a prospective exploratory study[J]. J Crohns Colitis, 2023, 17(9): 1387-1394. DOI: 10.1093/ecco-jcc/jjad068
[6] Bots S, Nylund K, Löwenberg M, et al. Ultrasound for assessing disease activity in IBD patients: a systematic review of activity scores[J]. J Crohns Colitis, 2018, 12(8): 920-929. DOI: 10.1093/ecco-jcc/jjy048
[7] Goodsall T M, Nguyen T M, Parker C E, et al. Systematic review: gastrointestinal ultrasound scoring indices for inflammatory bowel disease[J]. J Crohns Colitis, 2021, 15(1): 125-142. DOI: 10.1093/ecco-jcc/jjaa129
[8] Castiglione F, Mainenti P, Testa A, et al. Cross-sectional evaluation of transmural healing in patients with Crohn's disease on maintenance treatment with anti-TNF alpha agents[J]. Dig Liver Dis, 2017, 49(5): 484-489. DOI: 10.1016/j.dld.2017.02.014
[9] Castiglione F, Testa A, Rea M, et al. Transmural healing evaluated by bowel sonography in patients with Crohn's disease on maintenance treatment with biologics[J]. Inflamm Bowel Dis, 2013, 19(9): 1928-1934.
[10] Orlando S, Fraquelli M, Coletta M, et al. Ultrasound elasticity imaging predicts therapeutic outcomes of patients with Crohn's disease treated with anti-tumour necrosis factor antibodies[J]. J Crohns Colitis, 2018, 12(1): 63-70. DOI: 10.1093/ecco-jcc/jjx116
[11] De Voogd F, Bots S, Gecse K, et al. Intestinal ultrasound early on in treatment follow-up predicts endoscopic response to anti-TNFα treatment in Crohn's disease[J]. J Crohns Colitis, 2022, 16(10): 1598-1608. DOI: 10.1093/ecco-jcc/jjac072
[12] Calabrese E, Rispo A, Zorzi F, et al. Ultrasonography tight control and monitoring in Crohn's disease during different biological therapies: a multicenter study[J]. Clin Gastroenterol Hepatol, 2022, 20(4): e711-e722. DOI: 10.1016/j.cgh.2021.03.030
[13] Paredes J M, Moreno N, Latorre P, et al. Clinical impact of sonographic transmural healing after anti-TNF antibody treatment in patients with Crohn's disease[J]. Dig Dis Sci, 2019, 64(9): 2600-2606. DOI: 10.1007/s10620-019-05567-w
[14] Kucharzik T, Wittig B M, Helwig U, et al. Use of intestinal ultrasound to monitor Crohn's disease activity[J]. Clin Gastroenterol Hepatol, 2017, 15(4): 535-542. e2. DOI: 10.1016/j.cgh.2016.10.040
[15] Ripollés T, Paredes J M, Martínez-Pérez M J, et al. Ultrasonographic changes at 12 weeks of anti-TNF drugs predict 1-year sonographic response and clinical outcome in Crohn's disease: a multicenter study[J]. Inflamm Bowel Dis, 2016, 22(10): 2465-2473. DOI: 10.1097/MIB.0000000000000882
[16] Paredes J M, Ripollés T, Cortés X, et al. Abdominal sonographic changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's Disease[J]. Dig Dis Sci, 2010, 55(2): 404-410. DOI: 10.1007/s10620-009-0759-7
[17] Goertz R S, Klett D, Wildner D, et al. Quantitative contrast-enhanced ultrasound for monitoring vedolizumab therapy in inflammatory bowel disease patients: a pilot study[J]. Acta radiol, 2018, 59(10): 1149-1156. DOI: 10.1177/0284185117752032
[18] Quaia E, Sozzi M, Angileri R, et al. Time-intensity curves obtained after microbubble injection can be used to differentiate responders from nonresponders among patients with clinically active Crohn disease after 6 weeks of pharmacologic treatment[J]. Radiology, 2016, 281(2): 606-616. DOI: 10.1148/radiol.2016152461
[19] Quaia E, Gennari A G, Cova M A. Early predictors of the long-term response to therapy in patients with Crohn disease derived from a time-intensity curve analysis after microbub-ble contrast agent injection[J]. J Ultrasound Med, 2019, 38(4): 947-958. DOI: 10.1002/jum.14778
[20] Saevik F, Nylund K, Hausken T, et al. Bowel perfusion measured with dynamic contrast-enhanced ultrasound predicts treatment outcome in patients with Crohn's disease[J]. Inflamm Bowel Dis, 2014, 20(11): 2029-2037. DOI: 10.1097/MIB.0000000000000159
[21] Baumgart D C, Müller H P, Grittner U, et al. US-based real-time elastography for the detection of fibrotic gut tissue in patients with stricturing Crohn disease[J]. Radiology, 2015, 275(3): 889-899.
[22] Chen Y J, Chen B L, Liang M J, et al. Longitudinal bowel behavior assessed by bowel ultrasound to predict early response to anti-TNF therapy in patients with Crohn's disease: a pilot study[J]. Inflamm Bowel Dis, 2022, 28(Suppl 2): S67-S75.
计量
- 文章访问数: 290
- HTML全文浏览量: 46
- PDF下载量: 55
